Display options
Cite
Ferreira PE, Cavaco I, Gil JP. Pharmacogenetic tools for malaria and TB in the Developing World. Per Med. 2008;5(6):627-639doi: 10.2217/17410541.5.6.627.
Ferreira, P. E., Cavaco, I., & Gil, J. P. (2008). Pharmacogenetic tools for malaria and TB in the Developing World. Personalized medicine, 5(6), 627-639. https://doi.org/10.2217/17410541.5.6.627
Ferreira, Pedro Eduardo, et al. "Pharmacogenetic tools for malaria and TB in the Developing World." Personalized medicine vol. 5,6 (2008): 627-639. doi: https://doi.org/10.2217/17410541.5.6.627
Ferreira PE, Cavaco I, Gil JP. Pharmacogenetic tools for malaria and TB in the Developing World. Per Med. 2008 Nov;5(6):627-639. doi: 10.2217/17410541.5.6.627. PMID: 29788622.
Copy Download .nbib Format: NLM
Share it on

Per Med. 2008 Nov;5(6):627-639. doi: 10.2217/17410541.5.6.627.

Pharmacogenetic tools for malaria and TB in the Developing World.

Personalized medicine

Pedro Eduardo Ferreira, Isa Cavaco, José Pedro Gil

Affiliations

  1. Malaria Research, Department of Medicine, Karolinska Institutet, Rätzius väg 10, plan 5, 171 77 Stockholm, Sweden. [email protected].
  2. Institute of Biotechnology and Bioengineering, Centre of Molecular and Structural Biomedicine, University of Algarve, Portugal.
  3. Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Sweden.

PMID: 29788622 DOI: 10.2217/17410541.5.6.627

Abstract

Some of the largest therapeutic drug exposures in the planet involve drugs employed against malaria and TB, two main global infectious diseases. Amodiaquine for malaria and isoniazid for TB are two pivotal drugs in the management of these diseases. Both drugs have been associated with severe adverse events. Amodiaquine and isoniazid are metabolized polymorphically by CYP2C8 and N-acetyltransferase 2, respectively. The polymorphic genes coding for these enzymes presently represent the best candidates for the application of personal pharmacogenetics for these diseases. We review the main reasons for this view, while asking the pivotal question of whether it is presently possible for pharmacogenetic-based personalized medicine to be applied in the malaria and TB settings of the Developing World.

Keywords: CYP2C8; Developing World; N-acetyltransferase 2; NAT2; TB; adverse events; malaria; pharmacogenetics; translational medicine

Publication Types